Johnson & Johnson Raises Full-Year Sales Outlook Despite Medical Device Concerns
Despite a nearly 6% drop in its stock price following disappointing medical device sales, Johnson & Johnson (JNJ) reported strong third-quarter results with revenue and earnings exceeding analyst expectations. The company raised its full-year guidance for both operational sales growth and adjusted earnings per share. While the Medical Technology segment underperformed due to lower-than-expected revenue from orthopedic devices, it still accounts for less than a third of total sales. The stock's decline was exacerbated by comments from CFO Joe Wolk during an earnings call where he described MedTech results as 'disappointing.' However, analysts argue that the broader picture remains positive. The company is on track to become one of the largest oncology drug providers globally and has a strong dividend history. Johnson & Johnson's long-term strategy includes spinning off its DePuy Synthes orthopedics business in 2027 but this segment represents only about 15% of total revenue. The company remains optimistic, with management confident it can achieve $50 billion in oncology drug sales by 2030.
Tickers: $JNJ
Topics: medical_devices pharmaceuticals stock_performance
Read the full article at Motley Fool
Part of the story Sigma Foods Reports Record 3Q26 EBITDA and Raises Full-Year Guidance (21 articles)